LeMaitre Vascular (LMAT) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
The annual meeting is scheduled for June 2, 2025, with proxy materials available online to reduce environmental impact and costs.
Shareholders will vote on director elections, executive compensation, frequency of say-on-pay votes, and auditor ratification.
The board recommends voting for all director nominees, for executive compensation, every three years for say-on-pay, and for auditor ratification.
2024 financial results showed 14% sales growth, 46% net income growth, and a 14% dividend increase.
Voting matters and shareholder proposals
Proposal 1: Elect three Class I directors for three-year terms.
Proposal 2: Advisory vote to approve 2024 executive compensation.
Proposal 3: Advisory vote on frequency of future say-on-pay votes, with board recommending every three years.
Proposal 4: Ratification of Grant Thornton LLP as independent auditor for 2025.
Shareholder proposals for the 2026 meeting must be received by December 18, 2025.
Board of directors and corporate governance
Board consists of eight members divided into three classes, with annual elections for one class.
Five directors are independent per Nasdaq standards.
Board committees: Audit, Compensation, and Nominating & Corporate Governance, all composed of independent directors.
Board leadership combines CEO and Chairman roles; no lead independent director.
Director resignation policy requires any director not receiving a majority of votes to offer resignation.
Latest events from LeMaitre Vascular
- Double-digit growth, global expansion, and 15 years of dividend increases drive strong outlook.LMAT
Investor presentation27 Feb 2026 - Q4 2025 delivered strong growth and 2026 guidance calls for 12% sales growth and higher margins.LMAT
Q4 202526 Feb 2026 - Q2 sales up 11%, net income up 46%, gross margin 68.9%, and 2024 guidance raised.LMAT
Q2 20242 Feb 2026 - Q3 2024 sales and EPS surged on pricing, biologics, and direct sales, with raised guidance.LMAT
Q3 202417 Jan 2026 - Double-digit growth, margin expansion, and higher shareholder returns drive 2025 outlook.LMAT
Q4 202423 Dec 2025 - Q1 2025 saw 13% organic sales growth, margin gains, and a raised outlook amid global expansion.LMAT
Q1 202523 Dec 2025 - Shareholders to vote on directors, executive pay, and auditor at June 2025 annual meeting.LMAT
Proxy Filing1 Dec 2025 - Board urges support for three director nominees amid ongoing governance and diversity discussions.LMAT
Proxy Filing1 Dec 2025 - Q2 2025 sales grew 15% to $64.2M, with 70% margin and raised full-year guidance.LMAT
Q2 202523 Nov 2025